tbuckley/cabot-search huggingface dataset:
Phase I dosage-finding and pharmacokinetic (PK) study of intravenous topotecan and oral erlotinib in patients (pts) with refractory solid tumors
Authors: L. S. Schwartzberg, C. F. Stewart, P. Schaiquevich, P. Legenne, K. Bhatt, A. Johns, M. S. Walker
Journal: Journal of Clinical Oncology (2008)

2549 Background: Topotecan (TPT) is a substrate for efflux transporters of the ABC family. Erlotnib (E), a 4-aniloquinazole, inhibits ABCG2 at clinically achievable plasma concentrations. This phase I study was designed to determine the maximum tolerated dose (MTD) of this combination of two active anticancer drugs with ABC transporter modulation capability and assess PK interactions. Methods: Escalating dose levels (DL) of 3 pt cohorts each of TPT IV at 0.75 mg/m2 (DL 1); 1.0 mg/m2 (DL 2); and 1.25 mg/m2 (DL 3); day 1 -5 q 21 day cycle. E was added on cycle 1, day 2 at 150 mg po daily continuously. Serial plasma samples were obtained pre and post TPT day 1, cycle 1 and day 1, cycle 2 or 3 and 24 hr urine samples were obtained after cycle 1 and cycle 2. Dose-limiting toxicity (DLT) was defined as G4 hematologic and/or G3/4 nonhematologic toxicities. Results: 23 enrolled pts included 4 ovarian, 4 colorectal, 4 sarcoma, 4 small cell lung, and 7 other tumors; 16 were Caucasian and 7 African American. Median (range) prior treatment regimens was 3 (1–5). At DL 1, 0/3 pts had DLT and at DL 2 1/6 pts had DLT of febrile neutropenia (FN). At DL 3, 2/6 pts had DLTs (neutropenia and thrombocytopenia). MTD was determined at DL 2, TPT 1.0 mg/m2 + E 150 mg. Six additional pts were enrolled at DL 2 to assess PK on cycles 1 and 3. 2/6 had G4 neutropenia and thrombocytopenia. Across the total cycles delivered of 68, G4 hematologic toxicities were neutropenia 22%, FN 1%, anemia 1%, thrombocytopenia 6%. In cohort 3, G4 neutropenia occurred in 6/22 cycles (27%). No G4 nonhematologic toxicity was noted in > 5% of patients. 18 pts were evaluable for response: 7 pts had stable disease > 12 weeks, and 2 pts had a partial response. The median (range) TPT systemic clearance measured on day 1 of course 1 (without E) was 8.1 L/h/m2 (3.6 to 14.9) compared with 7.9 L/h/m2 (4.5 to 12.2) measured on day 1 of course 2 or 3 (with E). Initial analysis revealed no obvious relationship between TPT systemic exposure and toxicity. Conclusions: TPT and E can be given together at clinically effective doses with acceptable hematologic and nonhematologic toxicity. The addition of E has minimal effect on systemic TPT clearance. Further studies are needed to establish efficacy of this combination. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline
Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia.
Authors: Olatoyosi M. Odenike, John E. Godwin, Koen van Besien, Dezheng Huo, Patrick J. Stiff, Dorie Sher, Nicole Klekowski, Margaret Green, Richard A. Larson, Wendy Stock
Journal: Blood (2006)
TCT-508 Bioresorbable Vascular Sccafold For The Treatment Of Chronic Total Occlusion Lesions - Clinical Outcomes And Intracoronary Imaging Follow-Up
Authors: Jarosław Wójcik, Marek Jankiewicz, Andrzej Madejczyk, Krzysztof Wiórkowski
Journal: Journal of the American College of Cardiology (2015)
Caspase-3–dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells
Authors: Ioulia Vardaki, Claire Sanchez, Pedro Fonseca, Magnus Olsson, Dimitrios Chioureas, George Rassidakis, Anders Ullén, Boris Zhivotovsky, Magnus Björkholm, Theocharis Panaretakis
Journal: Blood (2016)
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Authors: Padmanee Sharma, Margaret K Callahan, Petri Bono, Joseph Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi N Pillai, Patrick A Ott, Filippo de Braud, Michael Morse, Dung T Le, Dirk Jaeger, Emily Chan, Chris Harbison, Chen-Sheng Lin, Marina Tschaika, Alex Azrilevich, Jonathan E Rosenberg
Journal: The Lancet Oncology (2016)
WT1 Levels At Diagnosis and POST-Induction Provide Prognostic Information in Adult De Novo AML. Results From the Spanish Cetlam Group.
Authors: Josep F Nomdedeu, Montserrat Hoyos, Maite Carricondo, Elena Bussaglia, Camino Estivill, Jordi Esteve, Mar Tormo, Rafael F Duarte, Olga Salamero, PAZ Queipo De Llano, Joan Bargay, Inmaculada Heras, Josep M Marti-Tutusaus, Andreu Llorente, Josep-Maria Ribera, David Gallardo, Anna Aventin, Salut Brunet, Jorge Sierra
Journal: Blood (2012)
Risk of Hepatitis B Virus (HBV) Reactivation and Efficacy of Antiviral Preemptive Therapy in Malignant Lymphoma Patients Who Have Resolved HBV.
Authors: Takeshi Maeda, Tomoaki Ueda, Tomoyasu Jo, Kazuya Okada, Yasuyuki Arai, Takahito Kawata, Takeshi Ito, Satoko Morita, Tatsuhito Onishi, Chisato Mizutani, Fumio Matsuyama, Yasunori Ueda
Journal: Blood (2009)
Current growth patterns in children and adolescents with thalassemia major
Authors: Raffaella Origa, Fabrice Danjou, Valeria Orecchia, Antonietta Zappu, Carlo Dessì, Maria Loreta Foschini, Giovan Battista Leoni, Paolo Moi, Maddalena Morittu, Anna Demurtas, Sandro Loche
Journal: Blood (2016)
Transformation plans are overambitious and will not work, say service leaders
Authors: Adrian O’Dowd
Journal: BMJ (2016)

NHS service leaders have warned that many of the much talked about sustainability and transformation plans (STPs) that have been prepared by 44 areas across England to improve care for their local populations are overambitious and will not work.

Witnesses at an evidence session of the parliamentary health committee on 11 October raised several concerns about how the STP process had been unfairly dominated by financial saving expectations. The inquiry into the current state of NHS finances was prompted by a report from the National Audit Office published in July.1

STPs are five year plans drawn up by clinical commissioning groups, NHS trusts, and local authorities in 44 areas identified as a geographical “footprints” covering all areas of NHS spending in England. Areas have to submit their final plans to NHS England this month.

Chris Hopson, chief executive of …
Nitarsone, Inorganic Arsenic, and Other Arsenic Species in Turkey Meat: Exposure and Risk Assessment Based on a 2014 U.S. Market Basket Sample
Authors: Keeve E. Nachman, David C. Love, Patrick A. Baron, Anne E. Nigra, Manuela Murko, Georg Raber, Kevin A. Francesconi, Ana Navas-Acien
Journal: Environmental Health Perspectives (2016)

Background:Use of nitarsone, an arsenic-based poultry drug, may result in dietary exposures to inorganic arsenic (iAs) and other arsenic species. Nitarsone was withdrawn from the U.S. market in 2015, but its use in other countries may continue.Objectives:We characterized the impact of nitarsone use on arsenic species in turkey meat and arsenic exposures among turkey consumers, and we estimated cancer risk increases from consuming turkey treated with nitarsone before its 2015 U.S. withdrawal.Methods:Turkey from three cities was analyzed for total arsenic, iAs, methylarsonate (MA), dimethylarsinate, and nitarsone, which were compared across label type and month of purchase. Turkey consumption was estimated from NHANES data to estimate daily arsenic exposures for adults and children 4–30 months of age and cancer risks among adult consumers.Results:Turkey meat from conventional producers not prohibiting nitarsone use showed increased mean levels of iAs (0.64 μg/kg) and MA (5.27 μg/kg) compared with antibiotic-free and organic meat (0.39 μg/kg and 1.54 μg/kg, respectively) and meat from conventional producers prohibiting nitarsone use (0.33 μg/kg and 0.28 μg/kg, respectively). Samples with measurable nitarsone had the highest mean iAs and MA (0.92 μg/kg and 10.96 μg/kg, respectively). Nitarsone was higher in October samples than in March samples, possibly resulting from increased summer use. Based on mean iAs concentrations in samples from conventional producers with no known policy versus policies prohibiting nitarsone, estimated lifetime daily consumption by an 80-kg adult, and a recently proposed cancer slope factor, we estimated that use of nitarsone by all turkey producers would result in 3.1 additional cases of bladder or lung cancer per 1,000,000 consumers.Conclusions:Nitarsone use can expose turkey consumers to iAs and MA. The results of our study support the U.S. Food and Drug Administration's removal of nitarsone from the U.S. market and further support its removal from the global marketplace.Citation:Nachman KE, Love DC, Baron PA, Nigra AE, Murko M, Raber G, Francesconi KA, Navas-Acien A. 2017. Nitarsone, inorganic arsenic, and other arsenic species in turkey meat: exposure and risk assessment based on a 2014 U.S. market basket sample. Environ Health Perspect 125:363–369; http://dx.doi.org/10.1289/EHP225
TCT-664 Prognostic Impact of Pacemaker Implantation after Transfemoral/Trancutaneous Aortic Valve Implantation – Lessons from a Large Single Centre Registry
Authors: Felix Woitek, Stephan Haussig, Norman Mangner, F. Schlotter, A. Lindner, David M. Holzhey, Georg Stachel, Robert Höllriegel, Friedrich-Wilhelm Mohr, Gerhard Schuler, Axel Linke
Journal: Journal of the American College of Cardiology (2015)
GW27-e0061 Study on the Reconstitution of BKCa Channel of Vascular Smooth Muscle cell in Planar Lipid Bilayers
Authors: Cheng Jun, Xiaorong Zeng, Xiaoqiu Tan, Jing Wen, Pengyun Li, Wen Zhou, Yan Yang
Journal: Journal of the American College of Cardiology (2016)
The influence of optimism, social support and anxiety on aggression in a sample of dermatology patients: an analysis of cross-sectional data
Authors: A.M.C. Coneo, A.R. Thompson, A. Lavda
Journal: British Journal of Dermatology (2016)

Individuals with visible skin conditions often experience stigmatization and discrimination. This may trigger maladaptive responses such as feelings of anger and hostility, with negative consequences to social interactions and relationships.To identify psychosocial factors contributing to aggression levels in dermatology patients.Data were obtained from 91 participants recruited from outpatient clinics in the north of England, U.K. This study used dermatology-specific data extracted from a large U.K. database of medical conditions collected by The Appearance Research Collaboration. This study looked at the impact of optimism, perceptions of social support and social acceptance, fear of negative evaluation, appearance concern, appearance discrepancy, social comparison and well-being on aggression levels in a sample of dermatology patients.In order to assess the relationship between variables, a hierarchical regression analysis was performed. Dispositional style (optimism) was shown to have a strong negative relationship with aggression (β = -0·37, t = -2·97, P = 0·004). Higher levels of perceived social support were significantly associated with lower levels of aggression (β = -0·26, t = -2·26, P = 0·02). Anxiety was also found to have a significant positive relationship with aggression (β = 0·36, t = 2·56, P = 0·01).This study provides evidence for the importance of perceived social support and optimism in psychological adjustment to skin conditions. Psychosocial interventions provided to dermatology patients might need to address aggression levels and seek to enhance social support and the ability to be optimistic.
Prognostic Significance of Molecular Remission Determined by Highly Specific PCR after Dose-Reduced Allogeneic Stem Cell Transplantation (SCT) in Patients with Multiple Myeloma.
Authors: Maria V. Zagrivnaja, Anita Badbaran, Paolo Corradini, Boris Fehse, Axel R. Zander, Nicolaus Kröger
Journal: Blood (2004)
Increased Activity of Prothrombinase Fgl-2 in Peripheral Blood Mononuclear Cells of Patients with B-Cell Lymphoma.
Authors: Ofir Wolach, Esther Rabizadeh, Doron Lederfein, Natalia Binkovski, Pia Raanani, Ofer Shpilberg, Aida Inbal
Journal: Blood (2012)
TCT-536 Neointimal Response to Everolimus-Eluting Bioresorbable Scaffolds Implanted at Bifurcating Coronary Segments: Insights from Optical Coherence Tomography
Authors: Takao Sato, Ralph Toelg, Mohamed El-Mawardy, Gert Richardt, Mohamed Abdel-Wahab
Journal: Journal of the American College of Cardiology (2015)
Successful Induction of Hematologic and Cytogenetic Remission with Gemtuzumab Ozogamicin (Mylotarg(R)) in Patients with Myeloid Blast Crisis of Chronic Myelogenous Leukemia in Refractory to Imatinib Mesylate and Chemotherapy.
Authors: Jingyu Weng, Xin Du, Shuijing Wu, Zesheng Lu, Zilu Huang, Wei Lin
Journal: Blood (2005)
Development of Standardized Approaches to Reporting of Minimal Residual Disease Data Using a Reporting Software Package Designed within the European LeukemiaNet (ELN).
Authors: Charlotte G Nyvold, Mette Oestergaard, Morten T Andersen, Jelena V Jovanovic, Veli Kairisto, Jan K Larsen, Yvonne G Morgan, Ugur Ozbek, Niels Pallisgaard, Heike Pfeifer, David Grimwade, Peter Hokland
Journal: Blood (2009)
Bcl-2 Protects against p53-Induced Apoptosis through Hdm2
Authors: Line Wergeland, Kevin B. Spurgers, Eystein Oveland, Torill Høiby, Manel Cascallo, Tsuyoshi Honda, James B. Lorens, Guillermina Lozano, Timothy J. McDonnell, Bjorn T. Gjertsen
Journal: Blood (2008)
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Authors: Paulina J. Paszkiewicz, Simon P. Fräßle, Shivani Srivastava, Daniel Sommermeyer, Michael Hudecek, Ingo Drexler, Michel Sadelain, Lingfeng Liu, Michael C. Jensen, Stanley R. Riddell, Dirk H. Busch
Journal: Journal of Clinical Investigation (2016)

The adoptive transfer of T cells that have been genetically modified to express a CD19-specific chimeric antigen receptor (CAR) is effective for treating human B cell malignancies. However, the persistence of functional CD19 CAR T cells causes sustained depletion of endogenous CD19+ B cells and hypogammaglobulinemia. Thus, there is a need for a mechanism to ablate transferred T cells after tumor eradication is complete to allow recovery of normal B cells. Previously, we developed a truncated version of the epidermal growth factor receptor (EGFRt) that is coexpressed with the CAR on the T cell surface. Here, we show that targeting EGFRt with the IgG1 monoclonal antibody cetuximab eliminates CD19 CAR T cells both early and late after adoptive transfer in mice, resulting in complete and permanent recovery of normal functional B cells, without tumor relapse. EGFRt can be incorporated into many clinical applications to regulate the survival of gene-engineered cells. These results support the concept that EGFRt represents a promising approach to improve safety of cell-based therapies.
GP who had one night stand with patient is suspended for a month
Authors: Clare Dyer
Journal: BMJ (2016)

A GP who had a one night stand with a depressed patient and reported herself to the General Medical Council after her husband found out has been suspended for one month by a fitness to practise tribunal.

Jean Paton Ker, 41, gave her mobile phone number to a 40 year old male patient who was depressed after the break-up of his relationship. She told a panel of the Medical Practitioners Tribunal Service that she had feared he might be suicidal and gave him the number after he said that he was reluctant to call the mental health crisis team.

She had already increased the dosage of his antidepressant medication after he said that he feared he would feel worse over the coming 2013 Christmas period. He texted her …
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer
Authors: Michael P. Chu, J. Randolph Hecht, Dennis Slamon, Zev A. Wainberg, Yung-Jue Bang, Paulo M. Hoff, Alberto Sobrero, Shukui Qin, Karen Afenjar, Vincent Houe, Karen King, Sheryl Koski, Karen Mulder, Julie Price Hiller, Andrew Scarfe, Jennifer Spratlin, Yingjie J. Huang, Saba Khan-Wasti, Neil Chua, Michael B. Sawyer
Journal: JAMA Oncology (2016)

Capecitabine is an oral cytotoxic chemotherapeutic commonly used across cancer subtypes. As with other oral medications though, it may suffer from drug interactions that could impair its absorption.To determine if gastric acid suppressants such as proton pump inhibitors (PPIs) may impair capecitabine efficacy.This secondary analysis of TRIO-013, a phase III randomized trial, compares capecitabine and oxaliplatin (CapeOx) with or without lapatinib in 545 patients with ERBB2/HER2-positive metastatic gastroesophageal cancer (GEC); patients were randomized 1:1 between CapeOx with or without lapatinib. Proton pump inhibitor use was identified by medication records. Progression-free survival (PFS) and overall survival (OS) were compared between patients treated with PPIs vs patients who were not. Specific subgroups were accounted for, such as younger age (<60 years), Asian ethnicity, female sex, and disease stage (metastatic/advanced) in multivariate Cox proportional hazards modeling. The TRIO-013 trial accrued and randomized patients between June 2008 and January 2012; this analysis took place in January 2014.Patients were divided based on PPI exposure.Primary study outcome was PFS and OS between patients treated with PPIs vs patients who were not. Secondary outcomes included disease response rates and toxicities.Of the 545 patients with GEC (median age, 60 years; 406 men [74%]) included in the study, 229 received PPIs (42.0%) and were evenly distributed between arms. In the placebo arm, PPI-treated patients had poorer median PFS, 4.2 vs 5.7 months (hazard ratio [HR], 1.55; 95% CI, 1.29-1.81, P < .001); OS, 9.2 vs 11.3 months (HR, 1.34; 95% CI, 1.06-1.62; P = .04); and disease control rate (83% vs 72%; P = .02) vs patients not treated with PPIs. In multivariate analysis considering age, race, disease stage, and sex, PPI-treated patients had poorer PFS (HR, 1.68; 95% CI, 1.42-1.94; P < .001) and OS (HR, 1.41; 95% CI, 1.11-1.71; P = .001). In patients treated with CapeOx and lapatinib, PPIs had less effect on PFS (HR, 1.08; P = .54) and OS (HR, 1.26; P = .10); however, multivariate analysis in this group demonstrated a significant difference in OS (HR, 1.38; 95% CI, 1.06-1.66; P = .03).Proton pump inhibitors negatively effected capecitabine efficacy by possibly raising gastric pH levels, leading to altered dissolution and absorption. These results are consistent with previous erlotinib and sunitinib studies. Whether PPIs affected lapatinib is unclear given concurrent capecitabine. Given capecitabine's prevalence in treatment breast cancer and colon cancer, further studies are under way.clinicaltrials.gov Identifier: NCT00680901.
TCT-622 Is there a therapeutic limit to sequential aortic valve-in-valve? Hydrodynamic analysis of sequential valve-in-valve using the novel Inovare prosthesis in surgical aortic bioprosthesis
Authors: Caio Cardoso, Diego F. Gaia, Matheus S. Santos, Thiago Vila Nova, Ademir Braz, Andre Lupp, Celso Avila, Daniel Alves, Pedro Saab Mota, Guilherme Lira, Marcus Vinicius Gimenes, Joao R. Breda, Enio Buffolo, Jose Honorio Palma
Journal: Journal of the American College of Cardiology (2015)
The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia
Authors: Krzysztof Giannopoulos, Malgorzata Zajac, Anna Dolnik, Stephany Correa, Konstanze Dohner, Richard F. Schlenk, Lars Bullinger
Journal: Blood (2013)
Induced Pluripotent Stem Cell Modeling of Sickle Cell Anemia
Authors: Sarah S Rozelle, Brenden W Smith, Efthymia Melista, Ehimen Aneni, Paola Sebastiani, Clinton T. Baldwin, Abdulrahman Alsultan, David H.K. Chui, Gustavo Mostoslavsky, Martin H. Steinberg, George J. Murphy
Journal: Blood (2012)
Letter to the editor: The first tick-borne encephalitis case in the Netherlands: reflections and a note of caution
Authors: Jan Clement, Katrien Lagrou, Veroniek Saegeman, Piet Maes, Marc van Ranst
Journal: Eurosurveillance (2016)

Preview this article: Letter to the editor: The first tick-borne encephalitis case in the Netherlands: reflections and a note of caution, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/21/39/eurosurv-21-30355-5-1.gif
TCT-66 Long-term Clinical Outcomes of Percutaneous Coronary Intervention Using Drug-Eluting Stent for Native Coronary Chronic Total Occlusion
Authors: Pil Hyung Lee, Mineok Chang, Cheol Hyun Lee, Yu Na Kim, Hee-Soon Park, Se Hun Kang, Jae-Hyung Roh, Sung-Han Yoon, Jung-Min Ahn, Soo-Jin Kang, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2015)
Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial.
Authors: E. Thiel, A. Korfel, P. Martus, L. Kanz, F. Griesinger, M. Rauch, L. Fischer, T. Pietsch, M. Bamberg, M. Weller
Journal: Journal of Clinical Oncology (2010)

8008 Background: High-dose methotrexate (HDMTX) is considered the standard of care for patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The role of whole-brain radiotherapy (WBRT) has remained controversial. Delayed neurotoxicity limits its acceptance as a standard of care. Methods: Immunocompetent patients with newly diagnosed PCNSL were randomized to chemotherapy followed by WBRT (arms A1, B1) or chemotherapy alone (A2, B2). After randomization, all patients were to receive 6 cycles HDMTX (4 g/m2, D1, biweekly) from 1999-2007 and HDMTX plus ifosfamide (1.5 g/m2, D3-D5, biweekly) thereafter. Patients achieving a complete response (CR) received either consolidating WBRT with 45 Gy in 1.5 Gy fractions (arm A1) or no further treatment (A2). Patients without CR received salvage WBRT (B1) or salvage chemotherapy using HD-cytarabine (B2) (4 × 3 g/m2/ 48 h, × 3 weeks). The goal of the trial was to demonstrate that the omission of WBRT from first-line treatment does not compromise overall survival (OS) as the primary endpoint. Results: 551 patients (median age 63 years) entered the study, and 537 received at least one course HDMTX-based chemotherapy. Of those, 66 died on HDMTX, 60 dropped out, 411 entered the post-HDMTX phase, and 318 were treated per protocol (PP population). For this PP population, median OS was 32.4 months in the chemotherapy+WBRT arm (A1+B1, n=154) and 37.1 months in the chemotherapy alone arm (A2+B2, n=164) (p=0.80). The median progression-free survival (PFS) was 18.3 and 12 months (p=0.13), respectively. Conclusions: This largest PCNSL trial ever performed world-wide showed no difference in OS when WBRT was omitted from HDMTX-based chemotherapy in patients with newly diagnosed PCNSL. No significant financial relationships to disclose.
TCT-367 Evolution of Plaque Volume and Lesion Morphology in Patients with Non-culprit Lesion-related Events: A serial VH-IVUS analysis from the PROSPECT study
Authors: Kohei Koyama, Gary S. Mintz, John McPherson, Naim Farhat, Bertil Wennerblom, Bernard De Bruyne, Patrick W. Serruys, Gregg W. Stone, Akiko Maehara
Journal: Journal of the American College of Cardiology (2015)
Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496
Authors: Ranjana Advani, Fangxin Hong, Leo I. Gordon, Randy D. Gascoyne, Henry Wagner, Richard T. Hoppe, Richard I Fisher, Nancy L. Bartlett, Brad S. Kahl, Patrick Stiff, Bruce D. Cheson, Andrew R Belch, Jonathan W. Friedberg, Jeannine Kassis, Kristie A. Blum, Thomas M. Habermann, Joseph Tuscano, Sandra J. Horning
Journal: Blood (2011)
TCT-219 Impact of prasugrel versus clopidogrel in ACS patients undergoing PCI with short or long stents: Results from the PROMETHEUS Study
Authors: Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Melissa Aquino, Timothy D. Henry, Annapoorna Kini, Samir Kapadia, Sunil Rao, Sandra Weiss, Joseph B. Muhlestein, Kanhaiya L. Poddar, Brian A. Baker, Stuart Y. Keller, Mark B. Effron, Jennifer Chao, Craig E. Strauss, Anthony DeFranco, William Weintraub, Roxana Mehran
Journal: Journal of the American College of Cardiology (2015)